Metformin

$Met 101

$0.0...0722

0.66%

Twitter (X) Telegram

SOL 7w9gX1WBAYs6KnTd5oZdNNDS887YcBo4yScj66dUpump

1h %

6h %

1.47%

24h %

0.66%

Market Cap

$7.2K

Volume 24h

$0.10

Liquidity

$9.3K

About Metformin

Metformin, a widely used drug for managing type 2 diabetes, has gained significant attention for its potential longevity benefits based on multiple preclinical and clinical studies. The interest in metformin as a longevity agent stems from its role in modulating pathways linked to aging and chronic diseases.

Security Scan

Automated scan — always DYOR.

AI Analysis

Metformin ($Met) attempts to bridge the gap between pharmaceutical research and decentralized AI by tokenizing interest in the generic diabetes drug's longevity applications. While preclinical studies suggest metformin may influence aging-related pathways, the project’s on-chain signals—low volume, minimal transactions, and no audits—hint at a speculative, early-stage experiment rather than a proven platform. Its Solana deployment aligns with current meme-coin trends, but the lack of clear utility outside a niche research narrative raises questions about its staying power.

Frequently Asked Questions

What is the market cap of Met?

The market cap of Metformin is $7.2K.

What is the 24-hour trading volume for Met?

The 24-hour trading volume for Met is $0.10.

How does Metformin’s AI integration actually work, and what problem does it solve beyond tokenizing a drug name?

The project’s AI angle appears hypothetical, as its on-chain data reveals no active smart contracts or documented AI tools beyond the token itself. A true AI integration would likely involve predictive modeling for drug efficacy, patient data analysis, or decentralized trials, but these features aren’t reflected in the project’s current state. Without visible code, partnerships, or roadmap details, its ‘AI’ label seems more aspirational than functional, resembling a branding tactic to attract speculative interest.

Is Metformin’s tokenomics or platform designed for longevity researchers, or is it purely a meme coin riding the pharmaceutical narrative?

The project’s transactional footprint—just 7 daily trades and $13K in liquidity—suggests it’s primarily operating in the speculative meme-coin space rather than engaging longevity researchers. A dedicated platform for the field would likely feature staking for clinical trial participation, governance for drug research funding, or utility for accessing study data, none of which are evident here. The mismatch between its health-focused narrative and its on-chain activity implies the token is leveraging metformin’s cultural cachet more than its scientific potential.

How does Metformin differentiate itself from similar longevity or pharmaceutical tokens like $LIFE or $LONGEVITY, which also target aging research?

Metformin sets itself apart by targeting a single, widely recognized drug rather than a broad longevity thesis, which could appeal to a niche audience familiar with the medication’s off-label uses. However, its lack of audits, minimal ecosystem engagement, and reliance on Solana’s meme-coin ecosystem—unlike $LIFE or $LONGEVITY, which may have more established communities—undermines its potential uniqueness. Without concrete features like drug discount programs or research grants tied to the token, $Met risks blending into the crowded noise of AI-pharma hybrids rather than standing out.

Token Stats

Chain SOL

Launch Date Nov 16, 2024

Age 1y

Decimals 6

Native Price 0.0...0113 SOL

24h Txns 7

Contract

7w9gX1WBAYs6KnTd5oZdNNDS887YcBo4yScj66dUpump

24h Sentiment

2 Buys (28.6%) 5 Sells (71.4%)

Buy / Trade